Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia.
Chloroquine
Crt
Drug resistance
Malaria
Piperaquine
Plasmodium falciparum
Plasmodium vivax
mdr1
Journal
International journal for parasitology. Drugs and drug resistance
ISSN: 2211-3207
Titre abrégé: Int J Parasitol Drugs Drug Resist
Pays: Netherlands
ID NLM: 101576715
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
03
12
2020
revised:
09
06
2021
accepted:
11
06
2021
pubmed:
2
7
2021
medline:
7
1
2022
entrez:
1
7
2021
Statut:
ppublish
Résumé
Drug resistant Plasmodium parasites are a major threat to malaria control and elimination. After reports of high levels of multidrug resistant P. falciparum and P. vivax in Indonesia, in 2005, the national first-line treatment policy for uncomplicated malaria was changed in March 2006, to dihydroartemisinin-piperaquine against all species. This study assessed the temporal trends in ex vivo drug susceptibility to chloroquine (CQ) and piperaquine (PIP) for both P. falciparum and P. vivax clinical isolates collected between 2004 and 2018, by using schizont maturation assays, and genotyped a subset of isolates for known and putative molecular markers of CQ and PIP resistance by using Sanger and next generation whole genome sequencing. The median CQ IC
Identifiants
pubmed: 34193398
pii: S2211-3207(21)00029-4
doi: 10.1016/j.ijpddr.2021.06.002
pmc: PMC8358472
pii:
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Protozoan Proteins
0
Quinolines
0
Chloroquine
886U3H6UFF
piperaquine
A0HV2Q956Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
46-56Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200909
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200909/Z/16/Z
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
J Infect Dis. 2017 Aug 15;216(4):468-476
pubmed: 28931241
N Engl J Med. 2009 Jul 30;361(5):540-1
pubmed: 19641219
Antimicrob Agents Chemother. 2015 Sep;59(9):5721-6
pubmed: 26149984
PLoS Med. 2016 Oct 4;13(10):e1002138
pubmed: 27701420
Trans R Soc Trop Med Hyg. 2007 Apr;101(4):351-9
pubmed: 17028048
Antimicrob Agents Chemother. 2012 Oct;56(10):5258-63
pubmed: 22850522
Ann Trop Med Parasitol. 1973 Jun;67(2):249-50
pubmed: 4578939
Antimicrob Agents Chemother. 2015 Aug;59(8):4631-43
pubmed: 26014942
Nat Genet. 2015 Mar;47(3):226-34
pubmed: 25599401
Lancet Infect Dis. 2019 Sep;19(9):943-951
pubmed: 31345709
Nat Commun. 2016 May 18;7:11553
pubmed: 27189525
PLoS One. 2007 Oct 31;2(10):e1089
pubmed: 17971853
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11672-7
pubmed: 26261345
Antimicrob Agents Chemother. 2011 Mar;55(3):961-6
pubmed: 21135175
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
Genome Biol Evol. 2017 Jun 1;9(6):1673-1686
pubmed: 28854635
Antimicrob Agents Chemother. 2010 Dec;54(12):5146-50
pubmed: 20876370
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
Nat Commun. 2018 Jul 3;9(1):2585
pubmed: 29968722
Antimicrob Agents Chemother. 2011 Sep;55(9):4461-4
pubmed: 21730116
Nat Genet. 2016 Aug;48(8):959-964
pubmed: 27348299
Antimicrob Agents Chemother. 2008 Mar;52(3):1040-5
pubmed: 18180357
Mol Cell. 2000 Oct;6(4):861-71
pubmed: 11090624
Mol Biochem Parasitol. 2000 Apr 30;108(1):13-23
pubmed: 10802315
Nature. 2015 Jun 18;522(7556):315-20
pubmed: 26085270
mBio. 2017 May 9;8(3):
pubmed: 28487425
Am J Trop Med Hyg. 2018 Mar;98(3):677-682
pubmed: 29345221
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
Mol Biochem Parasitol. 2006 Dec;150(2):219-28
pubmed: 16987557
Nat Commun. 2014 Nov 25;5:5521
pubmed: 25422853
Mem Inst Oswaldo Cruz. 1999 Nov-Dec;94(6):803-9
pubmed: 10585659
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29941635
Malar J. 2010 Dec 25;9:375
pubmed: 21184684
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28533239
Nat Commun. 2017 May 24;8:15159
pubmed: 28537265
Sci Transl Med. 2013 Mar 20;5(177):177ra37
pubmed: 23515079
Antimicrob Agents Chemother. 2014 Sep;58(9):5060-7
pubmed: 24913172
Wellcome Open Res. 2021 Feb 24;6:42
pubmed: 33824913
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
J Infect Dis. 2008 Aug 1;198(3):409-17
pubmed: 18582193
Antimicrob Agents Chemother. 2015 Oct;59(10):6117-24
pubmed: 26195523
Antimicrob Agents Chemother. 2020 Feb 21;64(3):
pubmed: 31843994
ACS Infect Dis. 2016 Dec 9;2(12):945-957
pubmed: 27641613
Nat Commun. 2018 May 2;9(1):1769
pubmed: 29720620
PLoS Negl Trop Dis. 2012;6(8):e1772
pubmed: 22880143
J Parasitol. 1979 Jun;65(3):418-20
pubmed: 383936
Antimicrob Agents Chemother. 2013 Jul;57(7):3121-30
pubmed: 23612201
J Med Chem. 2019 Mar 14;62(5):2485-2498
pubmed: 30715882
Biochemistry. 2020 Jul 14;59(27):2484-2493
pubmed: 32589406
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
J Infect Dis. 2019 Oct 22;220(11):1738-1749
pubmed: 30668735
Antimicrob Agents Chemother. 2009 Dec;53(12):5069-73
pubmed: 19770282
Antimicrob Agents Chemother. 2013 Apr;57(4):1723-9
pubmed: 23357760
Mol Microbiol. 2005 Feb;55(4):1285-95
pubmed: 15686571
N Engl J Med. 2014 Jul 31;371(5):484-5
pubmed: 25075853
Int J Parasitol Drugs Drug Resist. 2019 Apr;9:16-22
pubmed: 30580023
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710
Lancet Infect Dis. 2002 Apr;2(4):209-18
pubmed: 11937421
BMC Med. 2015 Dec 22;13:305
pubmed: 26695060
Expert Rev Anti Infect Ther. 2017 Jun;15(6):527-543
pubmed: 28355493
Lancet Infect Dis. 2018 Aug;18(8):874-883
pubmed: 29909069
J Infect Dis. 2014 Oct 1;210(7):1110-4
pubmed: 24723474
Trends Mol Med. 2015 Dec;21(12):776-788
pubmed: 26611336
Nature. 1990 May 17;345(6272):255-8
pubmed: 2185424
Malar J. 2019 Oct 10;18(1):344
pubmed: 31601222
PLoS Med. 2019 May 29;16(5):e1002815
pubmed: 31167228
Science. 1976 Aug 20;193(4254):673-5
pubmed: 781840